Affordable Access

deepdyve-link
Publisher Website

VEGF expression in residual tumor cells in orbital retinoblastoma (IRSS stage III) treated with NACT: a prospective study.

Authors
  • Radhakrishnan, Venkatraman
  • Kashyap, Seema
  • Singh, Lata
  • Bakhshi, Sameer
Type
Published Article
Journal
Pediatric Blood & Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Sep 01, 2012
Volume
59
Issue
3
Pages
567–569
Identifiers
DOI: 10.1002/pbc.24009
PMID: 22086846
Source
Medline
License
Unknown

Abstract

We prospectively evaluated vascular endothelial growth factor (VEGF) expression by immunohistochemistry in 22 consecutive IRSS stage III retinoblastoma patients who underwent enucleation after neoadjuvant chemotherapy (NACT). Positive VEGF expression was observed in 6/22 (27.3%) patients. VEGF expression was associated with local progression on MRI prior to enucleation (P = 0.004), pathological scleral (P = 0.023), and extra-scleral tumor extension (P = 0.009). EFS for VEGF positive and negative patients was 0% and 56.25%, respectively (P = 0.0002). OS for VEGF positive patients was 33.33% and 54.69% for VEGF negative patients (P = 0.207). Thus, VEGF in residual tumor cells post-NACT may represent poor response to NACT, potential for local invasion, and inferior outcome.

Report this publication

Statistics

Seen <100 times